New hope for Tough-to-Treat blood cancer patients in early drug trial
NCT ID NCT07336472
Summary
This early-stage study is testing a new drug called IBI3003 for people with multiple myeloma that has returned or stopped responding to at least three previous treatments. Researchers will first determine the safest and most effective dose, then evaluate how well the drug controls the cancer and what side effects it causes. The study will enroll up to 360 participants who have limited treatment options remaining.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.